SAN FRANCISCO--(

旧金山--(

BUSINESS WIRE

商业热线

)--

)--

Rubedo Life Sciences

鲁贝多生命科学

, an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, announced its clinical development plans for its lead candidate RLS-1496 at the 12

，一家由人工智能驱动的临床阶段生物技术公司，专注于发现和快速开发针对衰老细胞的选择性细胞再生药物，于12日宣布了其主要候选药物RLS-1496的临床开发计划

th

第

Annual

年度

Dermatology Summit

皮肤病学峰会

. RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues. Rubedo’s CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS, led a discussion on longevity science and its potential $600 billion addressable global market opportunity while moderating a panel that included other longevity science experts and investors.

.RLS-1496是一流的GPX4调节剂，可靶向衰老细胞和周围组织。鲁贝多首席执行官弗雷德里克·贝丁菲尔德（FrederickBeddingfield），III，医学博士，博士，FAAD，FACMS，领导了一场关于长寿科学及其潜在的6000亿美元可寻址全球市场机会的讨论，同时主持了一个由其他长寿科学专家和投资者组成的小组。

Rubedo’s Chief Scientific Officer Marco Quarta, PhD, also presented details regarding the Phase 1 clinical trial for RLS-1496, which will begin in Spring 2025 in the Netherlands, and the kickoff of the company’s Series B financing round..

Rubedo的首席科学官Marco Quarta博士还介绍了有关RLS-1496的第一阶段临床试验的详细信息，该试验将于2025年春季在荷兰开始，以及该公司B轮融资的启动。。

The Dermatology Summit, which Dr Beddingfield co-founded 12 years ago as part of the non-profit Advancing Innovation in Dermatology, was held alongside the J.P. Morgan Healthcare Conference 2025. Dr. Beddingfield also participated as a panelist at Biotech Showcase, discussing “Enhancing Longevity,” and at a J.P.

12年前，Beddingfield博士与人共同创立了皮肤病学峰会，该峰会是非营利性推进皮肤病学创新的一部分，与2025年摩根大通医疗保健会议同时举行。Beddingfield博士还作为小组成员参加了生物技术展示会，讨论了“延长寿命”以及J.P。

Morgan side event “Italy on the Move,” hosted by the Italian Trade Agency and the Ministry of Foreign Affairs and International Corporation. Rubedo is headquartered in Silicon Valley with offices in Milan, Italy..

由意大利贸易署、外交部和国际公司主办的摩根附带活动“意大利在行动”。鲁贝多总部位于硅谷，在意大利米兰设有办事处。。

“Today, more than 1 billion adults are over the age of 60 and this number is expected to increase to 2 billion by 2050

“今天，60岁以上的成年人超过了10亿，预计到2050年这一数字将增加到20亿

2

2

,” said Dr. Beddingfield. “Innovations to address the biological processes causing age-related chronic conditions, including heart disease, dementia, cancer, obesity, and metabolic syndrome, are needed to enable people to not only fight disease but also to empower a vibrant healthspan. At Rubedo, we are excited to be bringing the first selective cellular rejuvenation medicine that targets GPX4 into the clinic early this year.

”贝丁菲尔德博士说。“需要创新来解决导致与年龄有关的慢性病（包括心脏病、痴呆症、癌症、肥胖症和代谢综合征）的生物过程，使人们不仅能够抗击疾病，而且能够增强活力。在鲁贝多，我们很高兴今年年初将首个针对GPX4的选择性细胞再生药物引入临床。

Our vision is to help adults live longer and healthier lives and we are delighted to be at the forefront of this new era in longevity science.”.

我们的愿景是帮助成年人活得更长更健康，我们很高兴站在长寿科学新时代的前沿。”。

About Rubedo Life Sciences

关于鲁贝多生命科学

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders.

。我们专有的AI驱动的ALEMBIC™药物发现平台正在开发新型一流的小分子，以选择性靶向病理和衰老细胞，这些细胞在肺部，皮肤病，肿瘤学，神经退行性，纤维化和其他慢性疾病的进展中起关键作用。

Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – enters Phase I clinical trials.

我们的主要候选药物RLS-1496（一种潜在的一流疾病改变GPX4调节剂）进入了I期临床试验。

in Spring 2025. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy.

2025年春季。鲁贝多领导团队由化学、人工智能技术、长寿科学和生命科学领域的行业领导者和早期先驱组成，拥有大型制药公司和领先生物技术公司在药物开发和商业化方面的专业知识。该公司总部位于美国加利福尼亚州桑尼维尔，在意大利米兰设有办事处。

For additional information, visit .

有关更多信息，请访问。

www.rubedolife.com

www.rubedolife.com

.

.

1

1

Newman P. Longevity Technology

纽曼P.长寿科技

®

®

.

.

Bank of America analysts predict Longevity to be the opportunity of the decade.

美国银行（Bank of America）分析师预测，长寿将是这十年的机遇。

Published July, 2019. Accessed 13 January, 2025. Available:

2019年7月出版。2025年1月13日访问。可用：

https://longevity.technology/news/bank-of-america-analysts-predict-longevity-to-be-the-opportunity-of-the-decade/

https://longevity.technology/news/bank-of-america-analysts-predict-longevity-to-be-the-opportunity-of-the-decade/

2

2

World Health Organization. Key Facts

世界卫生组织。关键事实

. Published October 20, 2023. Accessed 13 January 2025. Available:

2023年10月20日出版。2025年1月13日访问。可用：

https://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults#:~:text=Overview,conditions%20at%20the%20same%20time

https://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults#:~：text=概述，条件%20at%20the%20ame%20time

October 20, 2023.

2023年10月20日。